758 related articles for article (PubMed ID: 20578895)
1. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
3. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
4. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
[TBL] [Abstract][Full Text] [Related]
5. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.
Kung AW; Yau CC; Cheng A
J Clin Endocrinol Metab; 1994 Aug; 79(2):542-6. PubMed ID: 7913934
[TBL] [Abstract][Full Text] [Related]
6. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
7. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
8. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
[TBL] [Abstract][Full Text] [Related]
9. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
[TBL] [Abstract][Full Text] [Related]
10. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
11. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
Bartalena L
J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
[TBL] [Abstract][Full Text] [Related]
12. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
[TBL] [Abstract][Full Text] [Related]
13. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
14. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
[TBL] [Abstract][Full Text] [Related]
15. Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
Kahaly GJ
J Clin Endocrinol Metab; 2020 Dec; 105(12):3704-20. PubMed ID: 32929476
[TBL] [Abstract][Full Text] [Related]
16. Impaired immune regulation after radioiodine therapy for Graves' disease and the protective effect of Methimazole.
Côté-Bigras S; Tran V; Turcotte S; Rola-Pleszczynski M; Verreault J; Rottembourg D
Endocrine; 2016 Jun; 52(3):587-96. PubMed ID: 26701678
[TBL] [Abstract][Full Text] [Related]
17. Radioactive iodine (RAI) treatment of hyperthyroidism is safe in patients with Graves' orbitopathy--a prospective study.
Król A; Koehler A; Nowak M; Paliczka-Cieślik E; Krajewska J; Kalemba M; Jurecka-Lubieniecka B; Hasse-Lazar K; Michalik B; Szpak-Ulczok S; Zarudzki Ł; Roskosz J; Jarząb B
Endokrynol Pol; 2014; 65(1):40-5. PubMed ID: 24549601
[TBL] [Abstract][Full Text] [Related]
18. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America.
Wartofsky L
Thyroid; 1997 Apr; 7(2):213-6. PubMed ID: 9133687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]